Thermo Fisher Scientific (TMO) Liabilities and Shareholders Equity (2009 - 2026)

Thermo Fisher Scientific has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $113.2 billion in Q2 2026.

• Liabilities and Shareholders Equity for Q2 2026 came in at $113.2 billion, up 11.8% year-over-year; the trailing twelve-month figure through Jun 2026 was $439.8 billion (up 10.52% YoY), and the FY2025 annual result was $110.3 billion, up 13.38% from the prior year.
• Liabilities and Shareholders Equity held at $113.2 billion in Q2 2026, from $113.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $113.3 billion in Q1 2026 and troughed at $90.5 billion in Q4 2022.
• A 5-year average of $99.4 billion and a median of $97.9 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity surged 40.67%; it then fell 1.42% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $97.2 billion in 2022, then advanced by 1.62% to $98.7 billion in 2023, then decreased by 1.42% to $97.3 billion in 2024, then climbed by 13.38% to $110.3 billion in 2025, then grew by 2.57% to $113.2 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $113.2 billion in Q2 2026, $113.3 billion in Q1 2026, and $110.3 billion in Q4 2025.